TNXP / Tonix Pharmaceuticals Holding Corp. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 27, 2026 TONIX PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 27, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com

EX-99.02

Exhibit 99.02

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology Phase 1 data support TNX-1500 as a potentially first-in-class

Exhibit 99.01 Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 © 2026 Tonix Pharmaceuticals Holding Corp. TNX - 4800: A Long - Acting, Bactericidal, Human Monoclonal Antibody to Prevent Lyme Disease in the U.S. Zeil Rosenberg MD, MPH Executive Vice President, Medical Tonix Pharmaceutical s Global Lyme Alliance PO6143 May 15, 2026 1660 2 © 2026 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 15, 2026 TONIX PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 15, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com

CERTIFICATION

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 11, 2026 TONIX PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 11, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36019 TONIX PHA

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q Exhibit 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Ph

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were fil

Tonix Pharmaceuticals Holding Corp. Form 8-K Exhibit 99.01 Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading group purchasing organization (GPO) that provides

CERTIFICATION

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 7, 2026 TONIX PHARMACEUTICALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 7, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Comm

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~

TONIX PHARMACEUTICALS HOLDING CORP. FORM 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.) TONMYA (cyclobenzaprine HCl sublingual tablets),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 6, 2026 TONIX PHARMACEUTICALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 6, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 1, 2026 TONIX PHARMACEUTICALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 1, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Comm

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposiu

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University Company on track to initiate a randomized, double-blind, placebo-c

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.02 Serum concentration, µg/mL Observed Phase 1 Pharmacodynamics Study participants randomized 1:1 to receive TNX - 4800 or placebo Dose 1 Tick Season Day 1 Day 60 6 months 2027 Planned TNX - 4800 Adaptive Phase 2 Field Study Design Dose 2 Surveillance Summary Conclusions Results References Design of Planned Phase 2 Study Multiple Approaches Inform

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 29, 2026 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 29, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and signif

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.1 Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models TNX-1

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.03

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 21, 2026 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 21, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.02

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 30, 2026 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 30, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.03 UMass Chan Medical School A Long - Acting Monoclonal Antibody for Seasonal Prevention of Lyme Disease Mark S. Klempner, MD Professor of Medicine March 30, 2026 World Vaccine Congress UMass Chan Medical School Disclosures Co - Inventor US Patent 10,457,721 Consultant Tonix Pharmaceuticals, Inc Support from N ational C enter for A dvancing T rans

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.02 © 2026 Tonix Pharmaceuticals Holding Corp. TNX - 4800: A Long - Acting , Borreliacidal (Bactericidal), Human Monoclonal Antibody to Prevent Lyme Disease in the U.S. NASDAQ: TNXP March 31, 2026 PO6131 March 31, 2026 1648 2 © 2026 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presen

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 TNX-4800 is a long-acting anti-Borrelia burgd

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain Intranasal oxytocin blocks t

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 26, 2026 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 26, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 16.1 March 18, 2026 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated March 18, 2026 of Tonix Pharmaceuticals Holding Corp. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 16, 2026 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 16, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

ANNUAL REPORT TO SECURITY HOLDERS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of regis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 12, 2026 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 12, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, mo

TONIX PHARMACEUTICALS HOLDING CORP Exhibit 99.01 Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA to patients, approximately 2,500 patients h

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharm

CERTIFICATION

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this annual report on Form 10-K of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which

CERTIFICATION

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this annual report on Form 10-K of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whi

SUBSIDIARIES OF THE COMPANY

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 21.01 SUBSIDIARIES OF THE COMPANY Subsidiary Name State/ Jurisdiction of Incorporation/Formation Tonix Pharmaceuticals, Inc. Delaware Krele, LLC Delaware Tonix Pharmaceuticals (Canada), Inc. New Brunswick, Canada Tonix Pharma Holdings Limited Ireland Tonix Pharma Limited Ireland Jenner Institute LLC Delaware Tonix R&D Center, LLC Delaware Tonix Medi

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements of Tonix Pharmaceuticals Holding Corp. on Form S-3 (Nos. 333-282270 and 333-287965) and Form S-8 (Nos. 333-202006, 333-212300, 333-219928, 333-226776, 333-232137, 333-239152, 333-257437, 333-265705, 333-272746, 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of r

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 4.02 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of all material characteristics of our common stock as set forth in our articles of incorporation and bylaws. The summary does not purport to be complete and is qualified in its entirety by reference to

Exclusive License Agreement

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 10.51 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS PRIVATE OR CONFIDENTIAL. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” Exclusive License Agreement This Exclusive License Agreement (this “Agreement”), effective as of the date last signed below (the “Effective Date”), is between the Unive

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post ho

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 10, 2026 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 10, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 3, 2026 TONIX PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 3, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market BERKELEY HEIGHTS, N.J., March 3, 2026 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that it has received approval from Nasda

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2026 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2026 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Exploring clinical development plan options including a controlled human infection mo

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-48

TONIX PHARMACEUTICALS HOLDING CORP. (a Nevada corporation) 615,025 Shares of Common Stock Pre-Funded Warrants to purchase up to 615,025 shares of Common Stock PLACEMENT AGENCY AGREEMENT

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 1.01 TONIX PHARMACEUTICALS HOLDING CORP. (a Nevada corporation) 615,025 Shares of Common Stock Pre-Funded Warrants to purchase up to 615,025 shares of Common Stock PLACEMENT AGENCY AGREEMENT December 29, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Tonix Pharmaceuticals Holding Corp., a Nevada corpor

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 December 29, 2025 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 079285 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corpo

SECURITIES PURCHASE AGREEMENT

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 10.01 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2025, between Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 29, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 29, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering CHATHAM, N.J., December 29, 2025 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase agreement with

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 5.02 December 29, 2025 Tonix Pharmaceuticals Holding Corp. 26 Main Street – Suite 101 Chatham, NJ 07928 Ladies and Gentlemen: We have acted as counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), in connection with the sale and issuance of (i) 615,025 shares (the “Shares”) of the Company’s common stock, par value $0.0

615,025 Shares of Common Stock Pre-Funded Warrants to Purchase 615,025 Shares of Common Stock 615,025 Shares of Common Stock underlying the Pre-Funded Warrants

Filed pursuant to Rule 424(b)(5) Registration No. 333-287965 PROSPECTUS SUPPLEMENT (To Prospectus dated September 4, 2025) 615,025 Shares of Common Stock Pre-Funded Warrants to Purchase 615,025 Shares of Common Stock 615,025 Shares of Common Stock underlying the Pre-Funded Warrants We are offering 615,025 shares of our common stock, par value $0.001 per share, or Common Stock, pursuant to this pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 29, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 29, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK TONIX PHARMACEUTICALS HOLDING CORP.

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 4.01 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK TONIX PHARMACEUTICALS HOLDING CORP. Warrant Shares: Original Issuance Date: December 30, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limita

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling studies

Exhibit 99.01 Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-ena

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 16, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 16, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 9, 2025 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 9, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.1 Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry CHATHAM, N.J., December 9, 2025 (GLOBE NEWSWIRE), Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated commercial-stage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 24, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 24, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode each year CHATHAM

TONIX PHARMACEUTICALS HOLDING CORP. AMENDMENT NO. 1 TO SALES AGREEMENT November 21, 2025

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 1.01 TONIX PHARMACEUTICALS HOLDING CORP. AMENDMENT NO. 1 TO SALES AGREEMENT November 21, 2025 This Amendment No. 1 (“Amendment No. 1”) amends that certain Sales Agreement, dated as of June 11, 2025 (the “Agreement”), by and between Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), and A.G.P./Alliance Global Partners, as sales

$250,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-282270 Registration No. 333-287965 PROSPECTUS SUPPLEMENT (To Prospectuses Dated September 30, 2024, and September 4, 2025) $250,000,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated June 11, 2025, filed as a part of our registration statement on Form S-3 (File No. 333-282270) (the “Prior

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 21, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 21, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 18, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 18, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 17, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 17, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYATM (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYATM (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-36019 TONIX

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine f

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 10, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 10, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 27, 2025 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 27, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital FOCUS is a randomized, double-blind, placebo-controlled cros

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 22, 2025 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 22, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 7, 2025 TONIX PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 7, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation October 2025 NASDAQ: TNXP PO6104 Mid October 2025 (Doc 16 21 ) © 2025 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or resu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 30, 2025 TONIX PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 30, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15

TONIX PHARMACEUTICALS HOLDING CORP Exhibit 99.01 Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 29, 2025 TONIX PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 29, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Version P0545 September 29, 2025 TNX - 2900 Prader - Willi Syndrome NASDAQ: TNXPJH1 2 © 2025 Tonix Pharmaceuticals Holding Corp. RARE DISEASE PORTFOLIO Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for futu

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (age

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 granted Orphan Drug a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 18, 2025 TONIX PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 18, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatm

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is FDA-approved for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 17, 2025 TONIX PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 17, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy re

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase 2/3 study Approximately 70 million people that are

EFFECT

X0101 EFFECT 33 LIVE 2025-09-04 16:30:00 S-3 0001430306 Tonix Pharmaceuticals Holding Corp. 333-287965

As filed with the Securities and Exchange Commission on September 4, 2025

As filed with the Securities and Exchange Commission on September 4, 2025 Registration No.

Tonix Pharmaceuticals Holding Corp. S-3/A

Tonix Pharmaceuticals Holding Corp. S-3/A Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Amendment No. 1 to the Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-3 (No. 333-287965) to be filed on or about September 4, 2025 of our report dated March 18, 2025, on our audits of the conso

Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928

Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 September 3, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-3 (File No. 333-287965) Filed on June 12, 2025 Ladies and Gentlemen: In accordance with

Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928

Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 September 3, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-3 (File No. 333-287965) Filed on June 12, 2025 Ladies and Gentlemen: Reference is made t

Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928

Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 August 29, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-3 (File No. 333-287965) Filed on June 12, 2025 Ladies and Gentlemen: In accordance with Ru

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 US Approval of Tonmya TM for the Treatment of Fibromyalgia August 18, 2025 NASDAQ: TNXP AGENDA + PARTICIPANTS Introduction, Fibromyalgia Overview & Tonmya TM Label Seth Lederman, M.D. – Chief Executive Officer and Chairman 01 02 03 Commercial and Go - To - Market Strategy Thomas Englese – EVP, Commercial & President, Tonix Medicines Q&A Seth Le

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 18, 2025 TONIX PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 18, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 15, 2025 TONIX PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 15, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated To

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces FDA Approval of TonmyaTM (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivo

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

TONIX PHARMACEUTICALS HOLDING CORP 10-Q Exhibit 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pha

CERTIFICATION

TONIX PHARMACEUTICALS HOLDING CORP 10-Q Exhibit 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whi

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first new drug for fibromyalgia in mor

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first new drug for fibromyalgia in more than 16 years  In June 2025, the Company was added to the Russell 3000® and Russell 2000® Inde

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 11, 2025 TONIX PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 11, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (

CERTIFICATION

TONIX PHARMACEUTICALS HOLDING CORP 10-Q Exhibit 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-36019 TONIX PHAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 25, 2025 TONIX PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 25, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 FOR IMMEDIATE RELEASE Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc.,

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 21, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

TONIX PHARMACEUTICALS HOLDING CORP

TONIX PHARMACEUTICALS HOLDING CORP Exhibit 99.01 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation July 2025 NASDAQ: TNXP PO6091 July 2025 (Doc 1608 ) 2 © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 16, 2025 TONIX PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 16, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immu

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.1 Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in animals Subcutaneous

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.2 TNX - 801, A SINGLE - DOSE LIVE VACCINE PLATFORM FOR MPOX AND OTHER EMERGING VIRAL DISEASES: SAFETY, IMMUNOGENICITY, AND EFFICACY Sina Bavari, Ph.D. World Congress on Vaccines July 10 th , 2025 © 2025 Tonix Pharmaceuticals Holding Corp. 2 © 2025 Tonix Pharmaceuticals Holding Corp. DISCLAIMER "Certain statements in this presentation regarding str

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 10, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 9, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine The previously disclosed and now published RESILIENT data show that once-nightly TNX-102

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyal

Pain Relief by Targeting Nonrestorative Sleep in Fibromyalgia: A Phase 3 Randomized Trial of Bedtime Sublingual Cyclobenzaprine

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 Pain Relief by Targeting Nonrestorative Sleep in Fibromyalgia: A Phase 3 Randomized Trial of Bedtime Sublingual Cyclobenzaprine Seth Lederman, MD1; Lesley M. Arnold, MD2; Ben Vaughn, MS3*; Jean M. Engels, MS1; Mary Kelley, MPH1; Gregory M. Sullivan, MD1 1Tonix Pharmaceuticals, Inc., Chatham, NJ, USA; 2University of Cincinnati College of Medicin

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 2, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric canc

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 16, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

LETTER

June 16, 2025 Seth Lederman Chief Executive Officer Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal deliver

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia: FDA PDUFA goal date of August 15, 2025 TNX-102

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 12, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry,

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix

As filed with the Securities and Exchange Commission on June 11, 2025

As filed with the Securities and Exchange Commission on June 11, 2025 Registration No.

Form of Senior Debt Indenture†

Tonix Pharmaceuticals Holding Corp. S-3 Exhibit 4.04 TONIX PHARMACEUTICALS HOLDINGS CORP., as Issuer and ●, as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between TONIX PHARMACEUTICALS HOLDINGS CORP. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and

Form of Subordinated Debt Indenture†

Tonix Pharmaceuticals Holding Corp. S-3 Exhibit 4.05 TONIX PHARMACEUTICALS HOLDINGS CORP., as Issuer and ●, as Trustee INDENTURE Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between TONIX PHARMACEUTICALS HOLDINGS CORP. and , as Trustee: Section of the Act Section of Indenture 310(a)(

Consent of EisnerAmper LLP†

Tonix Pharmaceuticals Holding Corp. S-3 Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-3 to be filed on or about June 11, 2025 of our report dated March 18, 2025, on our audits of the consolidated financial statements as of December 31

Calculation of Filing Fee Table†

Tonix Pharmaceuticals Holding Corp. S-3 Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) TONIX PHARMACEUTICALS HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Share(2) Maximum A

Consent of Brownstein Hyatt Farber Schreck, LLP (contained in Exhibit 5.02)

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 5.02 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 June 11, 2025 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporatio

Consent of Brownstein Hyatt Farber Schreck, LLP (contained in Exhibit 5.01)

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 June 11, 2025 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporatio

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 11, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

$75,000,000 and 48,708 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-282270 PROSPECTUS SUPPLEMENT (To Prospectus dated September 30, 2024) $75,000,000 and 48,708 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $75,000,000 of shares of our common stock, or Purchase Shares, that we may sell to Lincoln Park Capital Fund, LLC, or Lincoln Park, from time to time pursuant to

Sales Agreement, dated June 11, 2025, by and between Tonix Pharmaceuticals Holdings Corp. and A.G.P./Alliance Global Partners

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 1.01 Tonix Pharmaceuticals Holding Corp. COMMON STOCK SALES AGREEMENT June 11, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as follow

Registration Rights Agreement, dated June 11, 2025, by and between Tonix Pharmaceuticals Holding Corp. and Lincoln Park Capital Fund, LLC †

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 10.02 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 11, 2025, by and between TONIX PHARMACEUTICALS HOLDING CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms us

Up to $150,000,000 Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-282270 PROSPECTUS SUPPLEMENT (To Prospectus dated September 30, 2024) Up to $150,000,000 Common Stock On June 11, 2025, we entered into a certain sales agreement, or Sales Agreement, with A.G.P. / Alliance Global Partners, or A.G.P., relating to shares of our common stock offered by this prospectus. In accordance with the terms of the Sales Agr

Purchase Agreement, dated June 11, 2025, by and between Tonix Pharmaceuticals Holding Corp. and Lincoln Park Capital Fund, LLC †

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 10.01 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of June 11, 2025, by and between TONIX PHARMACEUTICALS HOLDING CORP., a Nevada corporation (the “Company”), LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Compan

Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.01)*

Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 May 30, 2025 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation

Consent of EisnerAmper LLP*

Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-8 to be filed on or about May 30, 2025 of our report dated March 18, 2025, on our audits of the consolidated financial statements as of December 31,

As filed with the Securities and Exchange Commission on May 30, 2025

As filed with the Securities and Exchange Commission on May 30, 2025 Registration No.

Filing Fee Table*

Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) TONIX PHARMACEUTICALS HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Line Item Type Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Pri

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 21, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR)

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University of North Carol

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the

TONIX PHARMACEUTICALS HOLDING CORP Exhibit 99.1 Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at Celgene Served

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 14, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treat

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36019 TONIX PHA

CERTIFICATION

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under

CERTIFICATION

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q Exhibit 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Ph

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 12, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 8, 2025 TONIX PHARMACEUTICALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 8, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Comm

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 29, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 Conclusion 1. Kim W, et al . PD - 1 Signaling Promotes Tumor - Infiltrating Myeloid - Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology. 2021 Feb;160(3):781 - 796. 2.Veglia F, et al . Analysis of classical neutrophils and polymorphonuclear myeloid - derived suppressor cells in cancer patients and tumor - bearing mice.

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-kil

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical developm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 25, 2025 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 25, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised anima

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination show

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 23, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 A NOVEL SINGLE - DOSE, LIVE ATTENUATED, MINIMALLY REPLICATIVE MPOX VACCINE Farooq Nasar, Ph.D., M.P.H. WVC April 23, 2025 PO6066 April 23, 2025 (Doc 1583) © 2025 Tonix Pharmaceuticals Holding Corp. Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looki

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies Agreement includes th

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 9, 2025 TONIX PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 9, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

Tonix Pharmaceuticals Launches TONIX ONETM, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

Tonix Pharmaceuticals 8k Exhibit 99.01 Tonix Pharmaceuticals Launches TONIX ONETM, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition Tonix expands its all-in-one platform, partnering with the world’s leading migraine diary app, enhancing disease education and prescription access CHATHAM, N.J., April 1, 2025 (GLOBE NEWSWIRE) – Tonix

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 1, 2025 TONIX PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 1, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 24, 2025 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 24, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation March 2025 NASDAQ: TNXP PO6052 March 21, 2025 (Doc 1569 ) 2 © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results a

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid anal

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

SUBSIDIARIES OF THE COMPANY

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 21.01 SUBSIDIARIES OF THE COMPANY Subsidiary Name State/ Jurisdiction of Incorporation/Formation Tonix Pharmaceuticals, Inc. Delaware Krele, LLC Delaware Tonix Pharmaceuticals (Canada), Inc. New Brunswick, Canada Tonix Pharma Holdings Limited Ireland Tonix Pharma Limited Ireland Jenner Institute LLC Delaware Tonix R&D Center, LLC Delaware Tonix Medi

CERTIFICATION

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this annual report on Form 10-K of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of r

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 18, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements of Tonix Pharmaceuticals Holding Corp. on Form S-3 (Nos. 333-266982 and 333-282270) and Form S-8 (Nos. 333-202006, 333-212300, 333-219928, 333-226776, 333-232137, 333-239152, 333-257437, 333-265705, 333-272746, a

BASE AGREEMENT ADVANCED TECHNOLOGY INTERNATIONAL (ATI) 315 SIGMA DRIVE SUMMERVILLE, SC 29486 Tonix Pharmaceuticals. Inc. 26 Main Street Suite 101 Chatham, NJ 07928 Unique Entity Identifier (UEI): JYPLHNCHF675

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 10.56 Page 1 of 52 BASE AGREEMENT BETWEEN ADVANCED TECHNOLOGY INTERNATIONAL (ATI) 315 SIGMA DRIVE SUMMERVILLE, SC 29486 AND Tonix Pharmaceuticals. Inc. 26 Main Street Suite 101 Chatham, NJ 07928 Unique Entity Identifier (UEI): JYPLHNCHF675 MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) BASE AGREEMENT NO.: 2023-493 Authority: MCDC Other Transaction Agreement

Exhibit 4.06

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 4.06 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of all material characteristics of our common stock as set forth in our articles of incorporation and bylaws. The summary does not purport to be complete and is qualified in its entirety by reference to

CERTIFICATION

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this annual report on Form 10-K of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharm

TONIX PHARMACEUTICALS HOLDING CORP. COMPENSATION RECOVERY POLICY (Adopted and approved on November 14, 2023)

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 97.01 TONIX PHARMACEUTICALS HOLDING CORP. COMPENSATION RECOVERY POLICY (Adopted and approved on November 14, 2023) 1. Purpose Tonix Pharmaceuticals Holding Corp. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulation

Attachment A Statement of Work

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 10.57 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS PRIVATE OR CONFIDENTIAL. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” Applied Technologies Center 315 Sigma Drive Summerville, SC 29486 www.ati.org PROJECT AGREEMENT NO.: 01 MCDC BASE AGREEMENT NO.: 2023-496 PROJECT TITLE: MCDC2215-006; D

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.1 Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash

STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Tonix Pharmaceuticals Holding Corp. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES

Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 19.01 STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Tonix Pharmaceuticals Holding Corp. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (coll

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate The World Health Organization (WHO) recently reaffirmed the spread of new clade

Tonix Pharmaceuticals Holding Corp. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related WHO PHEI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 10, 2025 TONIX PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 10, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K EXHIBIT 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Resurrecting Dr. Edward Jenner’s 1796 Horsepox Vaccine to Protect Against Mpox and Smallpox UT Southwestern Microbiology Department Seminar Seth Leder man, M.D. March 11, 2025 Version P06050 March 11, 2025 (Doc 1566) © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statem

Tonix Pharmaceuticals Form 8-K

Tonix Pharmaceuticals Form 8-K Exhibit 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Controversies in Fibromyalgia 2025 NASDAQ: TNXP Version P06048 March 3, 2025 (Doc 1564 ) Transmucosal Sublingual Cyclobenzaprine (TNX - 102 SL) Treatment of Fibromyalgia at Bedtime to Target Non - Restorative Sleep Showed Durable Pain Reduction in Two Double - Blind Randomized Phase 3 Studies March 3, 2025 2 ©

Dated February 27, 2025 TONIX PHARMA LIMITED SIOBHAN FOGARTY CONTRACT OF EMPLOYMENT Table of Contents

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 10.01 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS PRIVATE OR CONFIDENTIAL. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” Dated February 27, 2025 TONIX PHARMA LIMITED and SIOBHAN FOGARTY CONTRACT OF EMPLOYMENT Table of Contents 1 Definitions and interpretation 1 2 Appointment 1 3 Duties 1 4

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal deliv

Tonix Pharmaceuticals Form 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant impro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 27, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 27, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 3, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 20, 2025 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 20, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 7, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Compan

Tonix Pharmaceuticals Holding Corp 8-K Exhibit 99.01 Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities TNX-102 SL fibromyalgia FDA PDUFA goal date

Tonix Pharmaceuticals Holding Corp 8-K

Tonix Pharmaceuticals Holding Corp 8-K Exhibit 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation February 2025 NASDAQ: TNXP PO6043 Feb 6, 2025 (Doc 1559 ) 2 © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results ar

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases Results from the Phase 1 single as

Tonix Pharmaceuticals Holding Corp 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney tra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 6, 2025 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 6, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the managem

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia with U.S. FDA PDUFA goal date of August 15, 2025 CHATHAM, N.J., February 4,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2025 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2025 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Pay-Off Letter, dated February 3, 2025, by and among the Loan Parties, the Lenders and the JGB Agent

Tonix Pharmaceuticals Form 8-K Exhibit 10.01 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS PRIVATE OR CONFIDENTIAL. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” JGB Collateral LLC 246 Post Road East, 2nd Floor Westport, CT 06880 February 3, 2025 TONIX PHARMACEUTICALS HOLDING CORP. 26 Main Street Suite 101 Chatham, NJ 07928 Attention: Set

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split

Tonix Pharmaceuticals Form 8-K Exhibit 99.1 Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split CHATHAM, N.J., February 3, 2025 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will effect a 1-for-100 reverse st

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Admi

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal date of August

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 8, 2025 TONIX PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 8, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation January 2025 NASDAQ: TNXP PO6037 January 8, 2025 (Doc 1553 ) 2 © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or result

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 23, 2024 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 23, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track de

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 December 20, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the

$250,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-266982 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 30, 2024) $250,000,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated July 30, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-266982) (the “July 2024 Prospectus”), as previously supplemented by our prosp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 20, 2024 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 20, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been grant

Tonix Pharmaceuticals Holding Corp 8-K Exhibit 99.1 Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 17, 2024 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 17, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Holding Corp. S-8

Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-8 to be filed on or about December 6, 2024 of our report dated April 1, 2024, on our audits of the consolidated financial statements as of December

As filed with the Securities and Exchange Commission on December 6, 2024

As filed with the Securities and Exchange Commission on December 6, 2024 Registration No.

Calculation of Filing Fee Tables FORM S-8 (Form Type) TONIX PHARMACEUTICALS HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) TONIX PHARMACEUTICALS HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Title of Securities To Be Registered Amount To Be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price Amount of Regis

Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice Presiden

TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice President, Marketing, bringing over 25 years of marketing, sales and product planning experience to Tonix

TONIX PHARMACEUTICALS HOLDING CORP. 8-K/A

TONIX PHARMACEUTICALS HOLDING CORP. 8-K/A Exhibit 99.04 © 2024 Tonix Pharmaceuticals Holding Corp. TNX - 1500 Organ Transplant Rejection & Autoimmune Disorders NASDAQ: TNXP Version P06026 December 3, 2024 (Doc 1542) 2 © 2024 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objecti

TONIX PHARMACEUTICALS HOLDING CORP. 8-KA

TONIX PHARMACEUTICALS HOLDING CORP. 8-KA EXHIBIT 99.03 TNX - 102 SL Lead Indication : Fibromyalgia Additional Indication: Acute Stress Disorder NASDAQ: TNXP December 2024 © 2024 Tonix Pharmaceuticals Holding Corp. PO6027 December 3, 2024 (Doc 1539) Fibromyalgia Status: Two statistically significant Phase 3 studies completed; FDA granted Fast Track Designation • First pivotal Phase 3 study (RELIEF)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 3, 2024 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 3, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

TONIX PHARMACEUTICALS HOLDING CORP. 8-KA

TONIX PHARMACEUTICALS HOLDING CORP. 8-KA EXHIBIT 99.02

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 3, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation

TNXP / Tonix Pharmaceuticals Holding Corp. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

US8902608624 / Tonix Pharmaceuticals Holding Corp. / Alyeska Investment Group, L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 13, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals The World Health Organization (WHO) declare

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Se

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Bradley Saenger, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pharmaceuticals Holding Corp.

CERTIFICATION

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Design

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 12, 2024 TONIX PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 12, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-36019 TONIX

CERTIFICATION

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pharmaceuticals Holding Corp. o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 8, 2024 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 8, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 © 2023 Tonix Pharmaceuticals Holding Corp. © 2024 Tonix Pharmaceuticals Holding Corp. TNX - 1700 Gastric and Colorectal Cancers NASDAQ: TNXP Version PO6019 November 5, 2024 (Doc 1531 ) © 2023 Tonix Pharmaceuticals Holding Corp. 2 © 2024 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 4, 2024 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 4, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya Proposed clinical study in Kenya intended to test

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya Proposed clinical study in Kenya intended to test the safety, tolerability, and immunogenicity of TNX-801, a vaccine being developed to prevent mp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 1, 2024 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 1, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally re

Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals TNX-801, has characteristics th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 30, 2024 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 30, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 28, 2024 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 28, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) First payment received under Tonix’s contract with the Defe

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) First payment received under Tonix’s contract with the Defense Threat Reduction Agency (DTRA), for up to $34 million over five years CHATHAM, N.J., October

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 17, 2024 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 17, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with statistically significant resu

TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with statistically significant results on the primary endpoint of reducing widespread pain; generally well tolerated TNX-102 SL is

TNXP / Tonix Pharmaceuticals Holding Corp. / Empery Asset Management, LP - TONIX PHARMACEUTICALS HOLDING CORP. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tonix Pharmaceuticals Holding Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 890260847 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 16, 2024 TONIX PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 16, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally availab

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures Host-directed antiviral drugs have the p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 8, 2024 TONIX PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 8, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate i

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Septemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 27, 2024 TONIX PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 27, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation

LETTER

September 26, 2024 Seth Lederman Chief Executive Officer Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928

Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 September 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-3 (File No. 333- 282270) Filed on September 20, 2024 Ladies and Gentlemen: In accordanc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

TONIX PHARMACEUTICALS HOLDING CORP. - 8-K

TONIX PHARMACEUTICALS HOLDING CORP. - 8-K Exhibit 99.03 © 2024 Tonix Pharmaceuticals Holding Corp. Pharmacokinetic Properties of TNX - 102 SL, a Sublingual Formulation of Cyclobenzaprine Hydrochloride Bruce Daugherty, PhD 11 th Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024 – Oral Presentation September 19, 2024 Rome, Italy Version 1513 September 12, 2024 (P0601) 2 © 2024 Ton